Promotes Charles Huiner to Chief Operating Officer and Senior Vice President of Corporate Development & Strategy
Promotes Chief Financial Officer Matthew Pigeon to Chief Financial Officer and Senior Vice President
SANTA BARBARA, Calif., Feb. 01, 2016 -- Sientra, Inc. (NASDAQ:SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced the promotion of Charles Huiner to Chief Operating Officer and Senior Vice President of Corporate Development & Strategy, effective immediately. In addition to continuing to lead the Company’s business development and strategy, Mr. Huiner will assume responsibility for Sientra’s manufacturing operations, clinical operations and legal affairs functions.
The Company also announced the promotion of Matthew Pigeon to Senior Vice President in addition to his role as Chief Financial Officer and Treasurer.
Jeffrey Nugent, Chairman and Chief Executive Officer of Sientra, said, “Since joining the Sientra team in 2014, Charlie has demonstrated the ability to think strategically and facilitate a high level of cooperation and execution across the Company. His increased responsibilities at this time are critical to help coordinate the important cross functional priorities we have in front of us, including the ongoing development and execution of our manufacturing and supply chain strategy. Matt’s role in financial planning and control as well as the overall strategic direction of the Company will continue to be critical to our success. We congratulate both Charlie and Matt in their new roles and look forward to their continued contributions.”
About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company committed to making a difference in patients' lives by enhancing their body image, growing their self-esteem and restoring their confidence. The Company was founded to provide greater choice to board-certified plastic surgeons and patients in need of medical aesthetics products. The Company has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company sells its breast implants and breast tissue expanders exclusively to board-certified and board-admissible plastic surgeons and tailors its customer service offerings to their specific needs. The Company also offers a range of other aesthetic and specialty products.
Investor Contacts: The Ruth Group Nick Laudico / Brandon Vazquez (646) 536-7030 / 7032 [email protected]


TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court
Trump Says Anthropic No Longer Seen as National Security Threat
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 



